glp-1 compounding news november 2025 FDA takes aim at telehealth companies for promoting unofficial weight loss drug dupes Medscape | The investigational triple

Journal of Physiology and Pharmacology, 64(5), 597608

Efgartigimod-associated Kaposis varicelliform eruption and herpetic conjunctivitis in a patient with seropositive ocular myasthenia gravis: a case report and review

Participants were randomly assigned, 1:1:1, to once-weekly combination cagrilintide and semaglutide 2.4 mg, once-weekly semaglutide 2.4 mg plus placebo or once-weekly cagrilintide 2.4 mg plus placebo

Initial was the first determination after to enter at the study, and Final was the last determination

Qsymia is FDA-approved as a weight loss drug for adults with a BMI of 30 or greater, or a BMI of 27 or greater and a weight-related health condition

Gut microbes 17 , 2528429 (2025)